Brand name
Procardia XL, the original
We didn’t find a savings card or cash price from Procardia XL’s maker. Ask the pharmacy for Procardia XL’s cash price. With insurance, ask what your plan charges.
Generic name: nifedipine
Used for: High blood pressure · Chest pain from heart disease (angina) · Chest pain from heart artery spasms (vasospastic angina) · 2 more
From
$9.66 for 30 tablets
Generic nifedipine XL at Walgreens with the free Optum Perks coupon. Pick the strength on your label for its own price.
Rather have it mailed? From $21.51 for 30 tablets delivered ($16.51 plus $5 shipping) from Optum Perks. Make a free account, then have your prescription sent there.
Open Optum PerksA regular generic has the same active ingredient as Procardia XL, and the FDA requires it to work the same way.
Procardia XL, the original
We didn’t find a savings card or cash price from Procardia XL’s maker. Ask the pharmacy for Procardia XL’s cash price. With insurance, ask what your plan charges.
There isn’t one.
Same active ingredient as Procardia XL. Fillers and dyes can differ.
Pharmacies’ own cash prices for generic nifedipine, lowest first.
Pick up in storeDelivered
From each pharmacy’s own site, read November 17, 2026. Confirm the price before you fill.
Prices change, can differ by store and state, and may depend on the strength and how many you take. With insurance, ask what your plan charges; it can be less.
5 companies sell a generic of Procardia XL that the FDA rates a substitute. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.
Made by Alkem Laboratories
30 mg Pink, round, 9 mm, marked “ND30”
| Package | NDC |
|---|---|
| Bottle of 90 | 67877-757-90 |
| Bottle of 100 | 67877-757-01 |
| Bottle of 300 | 67877-757-58 |
| Bottle of 500 | 67877-757-05 |
60 mg Pink, round, 11 mm, marked “ND60”
| Package | NDC |
|---|---|
| Bottle of 90 | 67877-758-90 |
| Bottle of 100 | 67877-758-01 |
| Bottle of 300 | 67877-758-58 |
| Bottle of 500 | 67877-758-05 |
Inactive ingredients: ammonia, cellulose acetate, hydroxypropyl cellulose, propylene glycol, hypromellose 2910 (5 mpa.s), magnesium stearate, polyethylene glycol 400, polyethylene glycol 3350, polyethylene oxide 5000000, ferric oxide red, shellac, sodium chloride, titanium dioxide, ferrosoferric oxide, hypromellose 2910 (3 mpa.s), butylated hydroxytoluene
Has lactose · Made by Osmotica Pharmaceutical
30 mg Pink, round, 9 mm, marked “KU / 260”
| Package | NDC |
|---|---|
| Bottle of 90 | 62135-521-90 |
60 mg Pink, round, 10 mm, marked “KU / 261”
| Package | NDC |
|---|---|
| Bottle of 90 | 62135-522-90 |
Inactive ingredients: ferrosoferric oxide, cellulose acetate, silicon dioxide, hypromelloses, lactose monohydrate, magnesium stearate, cellulose, microcrystalline, polyethylene glycol, povidone, propylene glycol, ferric oxide red, sodium chloride, titanium dioxide, triacetin, polysorbate 20, polyethylene glycol 400
Has lactose · Made by Novast Laboratories
30 mg Yellow, round, 9 mm, marked “30”
| Package | NDC |
|---|---|
| Bottle of 30 | 50742-260-30 |
| Bottle of 100 | 50742-260-01 |
| Bottle of 300 | 50742-260-03 |
60 mg Light brown, round, 9 mm, marked “60”
| Package | NDC |
|---|---|
| Bottle of 30 | 50742-261-30 |
| Bottle of 100 | 50742-261-01 |
| Bottle of 300 | 50742-261-03 |
Inactive ingredients: cellulose, microcrystalline, lactose monohydrate, hypromelloses, ethylcelluloses, sodium lauryl sulfate, magnesium stearate, methacrylic acid - methyl methacrylate copolymer (1:1), polyethylene glycol 4000, talc, polyvinyl alcohol, titanium dioxide, lecithin, soybean, ferric oxide yellow, ferric oxide red, ferrosoferric oxide, methacrylic acid - methyl methacrylate copolymer (1:2), hydroxyethyl cellulose (2000 mpa.s at 1%)
Has lactose · Made by Osmotica Pharmaceutical
30 mg Pink, round, 9 mm, marked “KU / 260”
| Package | NDC |
|---|---|
| Bottle of 90 | 62175-260-46 |
| Bottle of 100 | 62175-260-37 |
| Bottle of 300 | 62175-260-55 |
60 mg Pink, round, 10 mm, marked “KU / 261”
| Package | NDC |
|---|---|
| Bottle of 90 | 62175-261-46 |
| Bottle of 100 | 62175-261-37 |
| Bottle of 300 | 62175-261-55 |
Inactive ingredients: ferrosoferric oxide, cellulose acetate, silicon dioxide, hypromelloses, lactose monohydrate, magnesium stearate, cellulose, microcrystalline, polyethylene glycol, povidone, propylene glycol, ferric oxide red, sodium chloride, titanium dioxide, triacetin, polysorbate 20, polyethylene glycol 400
Made by TWi Pharmaceuticals
Product page on upsher-smith.com
30 mg Pink, round, 9 mm, marked “T011”
| Package | NDC |
|---|---|
| Bottle of 300 | 24979-011-12 |
30 mg Pink, round, 9 mm, marked “T011”
| Package | NDC |
|---|---|
| Bottle of 100 | 24979-011-01 |
60 mg Pink, round, 10 mm, marked “T010”
| Package | NDC |
|---|---|
| Bottle of 300 | 24979-010-12 |
60 mg Pink, round, 10 mm, marked “T010”
| Package | NDC |
|---|---|
| Bottle of 100 | 24979-010-01 |
Inactive ingredients: hypromelloses, potassium chloride, povidone k30, sodium chloride, ferric oxide red, cellulose acetate, polyethylene glycol, magnesium stearate, ferrosoferric oxide, titanium dioxide, propylene glycol
The FDA doesn’t rate Aurobindo Pharma’s version of nifedipine a substitute for Procardia XL, so a pharmacy can’t swap it in without your prescriber’s OK.
Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.
“Before you fill my Procardia XL, can you tell me what I’d pay for the brand and for a generic?”
Paying cash? Ask for each one’s cash price. With insurance, ask what your plan charges for each.
Vasospastic Angina
PROCARDIA XL is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. PROCARDIA XL may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers.
Chronic Stable Angina (Classical Effort-Associated Angina)
PROCARDIA XL is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents.
In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete.
Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs (see WARNINGS).
Hypertension
PROCARDIA XL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including PROCARDIA XL.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
PROCARDIA XL may be used alone or in combination with other antihypertensive agents.
Source: the FDA label for Procardia XL (Pfizer Laboratories Div Pfizer Inc), September 21, 2026. Full label on DailyMed
Prices checked November 17, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/procardia-xl/